Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
52-week range
$13.49 – $17.30
13% from low
Exchange
OTC Link
OS
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $364.8M | $461.8M | $471.4M | $565.6M | $639.3M | $677.3M | $723.2M | $759.0M |
| Cost of revenue | $93.9M | $125.0M | $158.4M | $173.3M | $201.0M | $214.3M | $236.1M | $239.1M |
| Gross profit | $270.9M | $336.7M | $313.0M | $392.3M | $438.3M | $463.0M | $487.1M | $519.9M |
| Gross margin | 74.2% | 72.9% | 66.4% | 69.4% | 68.6% | 68.4% | 67.3% | 68.5% |
| R&D | $39.3M | $56.4M | $51.3M | $64.2M | $88.6M | $83.3M | $87.4M | $97.6M |
| Operating income | $111.6M | $126.6M | $110.3M | $162.7M | $158.3M | $167.1M | $177.7M | $202.1M |
| EBITDA | $113.8M | $150.9M | $134.4M | $193.6M | $190.9M | $207.2M | $219.8M | $236.7M |
| Net income | $88.7M | $99.2M | $89.5M | $125.3M | $118.3M | $130.3M | $140.7M | $153.1M |
| Net margin | 24.3% | 21.5% | 19.0% | 22.2% | 18.5% | 19.2% | 19.5% | 20.2% |
| EPS (diluted) | 3.72 | 4.16 | 3.75 | 5.25 | 4.96 | 5.46 | 5.90 | 6.42 |
Annual figures · source: Financial Modeling Prep
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $775M | $6.17 | $5.92–$6.51 | 1 |
| 2027 | $865M | $7.50 | $7.19–$7.91 | 1 |
| 2028 | $955M | $8.71 | $8.34–$9.18 | 1 |
Forward consensus · source: Financial Modeling Prep
CELLAVISION AB ORD
No one on the platform currently holds CLVSF.
No tracked institution reports a position in CLVSF as of their last filing.
| Ex-date | Per share | Pay date |
|---|---|---|
| 2026-04-30 | $2.7500 | 2026-05-06 |
| 2025-05-08 | $2.5000 | 2025-05-13 |
| 2024-05-06 | $2.2500 | 2024-05-13 |
No one on the platform has traded CLVSF yet.
| +0.00% |
| $428M |
| — |
| FDMDF4DMedical Limited | $3.00 | +0.00% | $1.8B | — |
| GSGTFGenSight Biologics S.A. | $0.09 | +0.00% | $15M | — |
Source: Financial Modeling Prep · peers by sector/industry
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.
Trading at 2.2× earnings vs its 3.6× historical median P/E.
Fair value ≈ $22.86 · price $14.00 today
Fair-value line = the stock's median historical P/E × earnings. Price below the orange line = cheap vs its own history; above = expensive. Not investment advice.